Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 15, 2023

BUY
$21.97 - $33.8 $549 - $844
25 Added 0.05%
51,242 $1.4 Million
Q2 2023

Aug 14, 2023

BUY
$21.44 - $25.15 $71,566 - $83,950
3,338 Added 6.97%
51,217 $1.14 Million
Q1 2023

May 15, 2023

BUY
$19.2 - $24.47 $919,276 - $1.17 Million
47,879 New
47,879 $1.04 Million
Q3 2022

Nov 14, 2022

BUY
$24.7 - $29.12 $851,087 - $1 Million
34,457 New
34,457 $883,000
Q3 2020

Nov 16, 2020

SELL
$12.46 - $19.98 $964,615 - $1.55 Million
-77,417 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$11.0 - $18.26 $1.05 Million - $1.75 Million
-95,643 Reduced 55.27%
77,417 $1.3 Million
Q1 2020

May 15, 2020

BUY
$10.11 - $14.04 $137,556 - $191,028
13,606 Added 8.53%
173,060 $2.06 Million
Q4 2019

Feb 14, 2020

SELL
$12.06 - $16.96 $191,850 - $269,799
-15,908 Reduced 9.07%
159,454 $1.93 Million
Q3 2019

Nov 14, 2019

SELL
$10.41 - $14.66 $644,420 - $907,512
-61,904 Reduced 26.09%
175,362 $2.48 Million
Q2 2019

Aug 14, 2019

BUY
$9.78 - $12.76 $213,262 - $278,244
21,806 Added 10.12%
237,266 $2.65 Million
Q1 2019

May 15, 2019

BUY
$10.03 - $15.71 $532,171 - $833,541
53,058 Added 32.67%
215,460 $2.53 Million
Q4 2018

Feb 14, 2019

BUY
$11.29 - $17.19 $1.53 Million - $2.34 Million
135,902 Added 512.84%
162,402 $2.17 Million
Q3 2018

Nov 14, 2018

BUY
$12.27 - $15.65 $325,155 - $414,725
26,500 New
26,500 $372,000
Q2 2018

Aug 14, 2018

SELL
$15.3 - $19.69 $158,569 - $204,067
-10,364 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$14.59 - $25.5 $151,210 - $264,282
10,364 New
10,364 $170,000
Q4 2017

Feb 14, 2018

SELL
$15.77 - $20.72 $547,755 - $719,688
-34,734 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$12.3 - $19.3 $427,228 - $670,366
34,734
34,734 $670,000

Others Institutions Holding CORT

About CORCEPT THERAPEUTICS INC


  • Ticker CORT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,105,000
  • Market Cap $5.92B
  • Description
  • Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...
More about CORT
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.